icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
XBdZ7z2pcU70bsNg